India, Oct. 18 -- Bengaluru-based Strides Pharma Science has announced that one of its step-down wholly owned subsidiary will market the world's firstWHO-prequalified generic version of subcutaneous depot medroxyprogesterone acetate (DMPA-SC)in Africa, strengthening women's access to affordable, quality reproductive health solutions.

Developed by Bangaldesh-based Incepta Pharmaceuticalsunder the brandMedogen SubQ, and supported by theChildren's Investment Fund Foundation (CIFF)and theGates Foundation, the WHO prequalification marks a major breakthrough in reproductive health access. It diversifies supply of DMPA-SC, breaking the single-source bottleneck and helping health systems procure at more affordable prices.

DMPA-SC is a three-mon...